Swiss National Bank purchased a new stake in Calithera Biosciences (NASDAQ:CALA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 45,300 shares of the biotechnology company’s stock, valued at approximately $378,000. Swiss National Bank owned 0.13% of Calithera Biosciences at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of CALA. Wells Fargo & Company MN raised its stake in Calithera Biosciences by 25.8% during the 3rd quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock worth $531,000 after acquiring an additional 6,910 shares in the last quarter. Trexquant Investment LP acquired a new position in Calithera Biosciences in the third quarter valued at $168,000. Dynamic Technology Lab Private Ltd increased its stake in Calithera Biosciences by 48.4% in the third quarter. Dynamic Technology Lab Private Ltd now owns 34,845 shares of the biotechnology company’s stock valued at $549,000 after purchasing an additional 11,368 shares during the period. Voya Investment Management LLC acquired a new position in Calithera Biosciences in the second quarter valued at $211,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Calithera Biosciences in the third quarter valued at about $239,000. 68.37% of the stock is owned by institutional investors and hedge funds.
CALA has been the topic of a number of research analyst reports. BidaskClub downgraded shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, January 18th. Zacks Investment Research cut shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. Leerink Swann reissued an “outperform” rating on shares of Calithera Biosciences in a research report on Friday. ValuEngine lowered shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Finally, Citigroup raised shares of Calithera Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $6.95 to $14.00 in a research report on Friday, February 16th. Three research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Calithera Biosciences has an average rating of “Hold” and a consensus price target of $18.00.
Shares of CALA stock traded down $0.40 during trading hours on Friday, reaching $5.45. The stock had a trading volume of 879,126 shares, compared to its average volume of 528,710. The stock has a market cap of $195.15, a PE ratio of -6.49 and a beta of 2.62. Calithera Biosciences has a twelve month low of $5.35 and a twelve month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, March 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.09). Calithera Biosciences had a negative net margin of 107.21% and a negative return on equity of 17.49%. The company had revenue of $7.24 million during the quarter, compared to the consensus estimate of $7.28 million. During the same quarter in the prior year, the company earned ($0.45) EPS. analysts expect that Calithera Biosciences will post -1.21 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/45300-shares-in-calithera-biosciences-inc-cala-acquired-by-swiss-national-bank.html.
About Calithera Biosciences
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.